Latest Safety News

Neurizon Therapeutics has secured an additional A$2.7 million through a placement addressing the shortfall from its entitlement offer, lifting total proceeds to approximately A$8.5 million. This fresh capital strengthens the biotech’s balance sheet and provides financial flexibility as it advances its lead ALS drug NUZ-001 through pivotal clinical stages.

Radiopharm Theranostics has finished enrolling patients in its U.S. Phase 2b trial of RAD 101 for brain metastases imaging, reporting promising interim data showing 90% concordance with MRI. The company aims to launch a pivotal Phase 3 trial following a full data readout in June 2026.

Aquirian’s Drillforce subsidiary has secured a $48 million, three-year drilling and blasting contract at Brightstar’s Lord Byron mine, marking a significant expansion of their strategic partnership in Western Australia’s Goldfields region.

Genesis Minerals posted robust March quarter results with 67,497oz gold production and a cash pile nearing A$600 million, while accelerating development at Tower Hill and preparing to close a transformative A$639 million acquisition of Magnetic Resources.

Brightstar Resources has secured a five-year strategic agreement with Aquirian Limited to supply drill and blast services at its Goldfields Hub, leveraging patented technology to optimise open pit mining efficiency and safety.

Ora Banda Mining delivered a record 38,800 ounces of gold in the March quarter, generating $76.3 million in free cash flow and boosting cash reserves to $231.7 million. The company also reported a tenfold increase in its Round Dam Mineral Resource to 1.33 million ounces, underpinning its aggressive growth strategy.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.

Scott Technology delivered a solid HY26 with 7% EBITDA growth to $13 million, driven by strong performances in Materials Handling and Mining, offsetting softness in Protein and Appliances. Forward work rose to $177 million, underpinning expectations for a stronger second half despite geopolitical uncertainties.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Qoria Limited and Aura have pushed back their merger timeline to July 2026 amid transaction complexities, with Aura providing a A$10 million unsecured working capital facility to support Qoria through the interim period.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.